Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals

Aurinia Pharmaceuticals Inc.

eGFR stable over 36 months; +2.7 mL/min vs control from baseline.
Serious AE rates: 19% voclosporin vs 24% control; 0 deaths in voclosporin arm vs 4 in placebo.
Mean UPCR lower in voclosporin group at all time points over 3 years.
Withdrawal rate: 12.9% voclosporin vs 15.0% control; drug well tolerated.
AURORA 2 enrolled 216 LN patients; 90 voclosporin and 78 control completed 36 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.